TY - JOUR T1 - Induction of trained immunity by influenza vaccination - impact on COVID-19 JF - medRxiv DO - 10.1101/2021.09.03.21263028 SP - 2021.09.03.21263028 AU - Priya A. Debisarun AU - Katharina L. Gössling AU - Ozlem Bulut AU - Gizem Kilic AU - Martijn Zoodsma AU - Zhaoli Liu AU - Marina Oldenburg AU - Nadine Rüchel AU - Bowen Zhang AU - Cheng-Jian Xu AU - Patrick Struycken AU - Valerie A.C.M. Koeken AU - Jorge Domínguez-Andrés AU - Simone J.C.F.M. Moorlag AU - Esther Taks AU - Philipp N. Ostermann AU - Lisa Müller AU - Heiner Schaal AU - Ortwin Adams AU - Arndt Borkhardt AU - Jaap ten Oever AU - Reinout van Crevel AU - Yang Li AU - Mihai G. Netea Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/10/2021.09.03.21263028.abstract N2 - Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate immunity, termed trained immunity, has been proposed as one of the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination and COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received a previous influenza vaccination: relative risk reductions of 37% and 49% were observed following influenza vaccination during the first and second COVID-19 waves, respectively. The quadrivalent inactivated influenza vaccine induced a trained immunity program that boosted innate immune responses against various viral stimuli and fine-tuned the anti-SARS-CoV-2 response, which may result in better protection against COVID-19. Influenza vaccination led to transcriptional reprogramming of monocytes and reduced systemic inflammation. These epidemiological and immunological data argue for potential benefits of influenza vaccination against COVID-19, and future randomized trials are warranted to test this possibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMGN was supported by a Spinoza Grant of the Netherlands Association for Scientific Research and an ERC Advanced Grant (#833247). YL was supported by an ERC starting Grant (#948207) and a Radboud University Medical Centre Hypatia Grant (2018). PNO, LM and HS were supported by the Jurgen Manchot Foundation. KLG was supported by the German Research Foundation (DFG # 428917761). MO was supported by the Research Committee of the Heinrich Heine University Duesseldorf. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Observational study: The Radboudumc databases on influenza vaccination status and COVID-19 incidence among employees were provided by the Department of Occupational Health and Safety. Giving the observational nature of this study, ethical waiver was obtained from the Arnhem-Nijmegen Ethical Committee. Ex-vivo study: . Ethical approval was obtained from the Duesseldorf Ethical Committee (study ID 2018_199, amendment 2018-199_1- (5/2020), and amendment 2018_199_2 (12/2020)).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes(Single-cell) sequencing data have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001005446. Olink proteomics data have been deposited to the Immport database under the study number SDY1799. ER -